Document:

Exhibit 10.38

 

LITIGATION
FUNDING AND INDEMNIFICATION agreement

 

This Litigation Funding
and Indemnification Agreement, dated as of ____, 2020, is by and between PBM RG Holdings, LLC, a Delaware limited liability
company (“Holdings”), and RareGen, LLC, a Delaware limited liability company (“RareGen,”
and together with Holdings, the “Parties”).

 

ARTICLE I

DEFINITIONS

 

1.1              
Definitions. The following capitalized terms shall have the meanings specified in this Section 1.1. Other
terms are defined in the text of this Agreement and those terms shall have the meanings respectively assigned to them.

 

“Affiliate”
means, with respect to any Person, any other Person that directly or indirectly Controls, is Controlled by, or is under common
Control with such Person.

 

“Agreement”
means this Litigation Funding and Indemnification Agreement, as amended from time to time in accordance with Section 12.7.

 

“Business
Day” means any day other than a day on which the Securities and Exchange Commission shall be closed.

 

“Business
Deal” means any transaction or arrangement relating to the Litigation or the Claims entered into by RareGen and any Person,
whereby such Person provides a benefit to RareGen or any of RareGen’s Affiliates, including any transaction or arrangement
with any Defendant.

 

“Claims”
means the claims that RareGen and Sandoz have against each Defendant in the Litigation and any related claims, including any claims
brought against or between RareGen and/or Sandoz in the Litigation.

 

“Collateral”
shall have the meaning assigned to such term in Section 10.1.

 

“Confidential
Information” means any information relating to: (a) the Transaction Documents, including any discussions and negotiations
related thereto, the existence of them, or the identity of the Parties or their respective Affiliates and owners; the Litigation
or the Claims, including the names of the parties and potential other parties to the Claims; the factual, legal, technical, economic
and financial background of the Claims; the procedural status of the Claims; the planned legal and procedural strategies and tactics
for the pursuing of the Claims or Settlement, or a Business Deal, or collection of the Litigation Proceeds; and the expected recoveries
from the Claims; (b) factual information, evidentiary information, legal theories, procedures, decision trees, experts’
or other consultants’ reports, attorney or other professional work product; (c) billing arrangements, billing rates, financial
arrangements, contingent fee agreements, contingent fee percentages, costs, finances, investments, investors, price lists, pricing,
profit margins, profitability and quotations; (d) any financial statements and information, data, documents, reports and materials
relating to the Litigation or the Claims; (e) information concerning accountants, agents, law firms, lawyers and advisors; and
(f) other proprietary or nonpublic information, data or material, in all cases regardless of whether such information is (i) written
or oral, irrespective of the form or storage medium, and (ii) specifically identified as “confidential” or which,
by virtue of its nature, would be understood to be confidential by a reasonable Recipient. “Confidential Information”
includes analytics derived from other Confidential Information. “Confidential Information” does not include information
that (x) was or becomes generally available to the public other than as a result of a disclosure by the Recipient in violation
of this Agreement; (y) was actually known to the Recipient on a non-confidential basis prior to its disclosure; or (z) was developed
independently of, and without use of or reference to, the Confidential Information or information derived from the Confidential
Information.

 

    1

     

    

 

“Control”
(including the terms “Controlled by” and “under common Control with”) means the possession, directly or
indirectly, of the power to direct or cause the direction of the management policies or affairs of a Person, whether through ownership
of voting securities of a Person, by contract or otherwise.

 

“Counsel”
means Current Counsel and/or any New Counsel.

 

“Counsel Fees”
means any and all fees payable by RareGen to Counsel for legal services related to the Litigation.

 

“Court”
means the courts or other tribunals in which the Litigation is conducted.

 

“Current Counsel”
means Quinn Emanuel Urquhart & Sullivan, LLP.

 

“Default Rate”
means a rate per annum equal to the lesser of (a) 9% per annum compounded monthly and (b) the highest applicable rate permitted
by law.

 

“Defendant”
means United Therapeutics, Smiths, any of their respective Affiliates, and any other defendant to the Litigation, and each of the
successors and assigns of the foregoing.

 

“Deployment”
shall have the meaning assigned to such term in Section 2.1.

 

“Deployment
Request” shall have the meaning assigned to such term in Section 2.3.

 

“Disclosing
Party” means the Party to this Agreement who provides Confidential Information to the Recipient.

 

“Encumbrance”
means any mortgage, pledge, lien, security or ownership interest, charge, hypothecation, or other encumbrance, option agreement,
transfer, set-off right, security or subordination arrangement, or other similar interest or arrangement of any kind.

 

“Engagement
Agreements” means all engagement and any other agreements with Counsel entered into by RareGen (and, if applicable, Holdings)
in connection with the Claims and the Litigation, including any amendments or modifications thereto.

 

“Final Resolution”
means the resolution of the Litigation that substantially concludes the Litigation with respect to RareGen pursuant to (a) a final,
non-appealable, legal and valid judgment of the Court binding all Defendants, or (b) a Settlement agreement or agreements between
RareGen and all Defendants.

 

“Governmental
Authority” means any court, tribunal, arbitrator, authority, agency, commission, official, body or other instrumentality
of the United States, any foreign country, or any domestic or foreign state, province, county, city, other political subdivision
or any other similar body or organization exercising governmental or quasi-governmental power or authority.

 

“Holdings”
shall have the meaning assigned to such term in the introduction to this Agreement.

 

“Holdings’
Share” means an amount equal to the Litigation Proceeds, less (i) any and all amounts payable to Senior Funder pursuant
to the terms of the Senior Funder Agreement, and (ii) any and all Litigation Expenses and Counsel Fees that are then payable by
Holdings pursuant to Article II of this Agreement and for which RareGen has not been reimbursed for pursuant to this Agreement.

 

    2

     

    

 

“Litigation”
means the case captioned Sandoz Inc. and RareGen, LLC v. United Therapeutics Corporation and Smiths Medical ASD, Inc., No. 3:19-cv-10170,
filed in April 2019 in the District Court of New Jersey, including the same if transferred to any other jurisdictions or forums
(arbitral, judicial or otherwise), together with (a) any and all claims, suits, causes of action, proceedings, and other rights
relating to, or arising therefrom, (b) any and all appellate proceedings, proceedings on remand, and enforcement, ancillary, parallel
or alternate dispute resolution proceedings and processes arising out of or related thereto, and (c) any additional cases, lawsuits,
arbitration matters or other proceedings filed or initiated by or on behalf of RareGen or any of RareGen’s Affiliates against
Defendants based upon the same or substantially similar facts.

 

“Litigation
Expenses” means reasonable out-of-pocket costs incurred by or on behalf of RareGen related to the Litigation, including
expert witness fees and costs, and any costs, fees, penalties or financial sanctions that become due and payable as a result of
the Litigation. Litigation Expenses shall not include Counsel Fees.

 

“Litigation
Proceeds” means any and all proceeds, receivables, property, cash, concessions and other consideration actually paid
or transferred directly or indirectly to or for the benefit of RareGen or any of RareGen’s Affiliates in connection with
the Litigation, the Promotion Agreement (solely to the extent related to the Litigation) or any Claims (whether by judgment, Settlement,
Business Deal, any payment under the Promotion Agreement (solely to the extent related to the Litigation) or otherwise), including,
to the extent consistent with the foregoing, any damages (punitive or otherwise), penalties, interest, award of attorneys’
fees and the reimbursement for costs and expenses, and other amounts paid or property transferred or concessions made to or for
the benefit of RareGen or any of RareGen’s Affiliates in respect of the Litigation, the Promotion Agreement (solely to the
extent related to the Litigation) or any Claims; provided, however, that any such proceeds, receivables, property, cash, concessions
and other consideration that is payable by RareGen to Sandoz under the terms of the Promotion Agreement shall be deemed not to
be Litigation Proceeds. The Litigation Proceeds will be calculated and determined without taking into consideration and prior to
deduction of (a) any Taxes payable by RareGen or any of RareGen’s Affiliates in connection with the Litigation Proceeds,
(b) setoffs of any kind, including setoffs in respect of any claim or counterclaim asserted against RareGen or any of RareGen’s
Affiliates by any Person, and (c) fees and/or expenses incurred in connection with the Litigation or the collection of any Litigation
Proceeds. Notwithstanding anything to the contrary in this Agreement, any of the following items received from Smiths or its Affiliates
shall be deemed not to be “Litigation Proceeds”, shall be expressly excluded from this definition and shall be disregarded
for purposes of calculating Holdings’ Share: (i) any and all cartridges, (ii) the specifications for Smiths’ cartridges,
(iii) copies of release test methods and release specifications used by Smiths for its cartridges, (iv) copies of the standard
operating procedures and manufacturing methods used by Smiths in the manufacture of Smiths’ cartridges, (v) a copy of Smiths’
full, unredacted 510(k) for its cartridges and/or pump, (vi) a license to copy Smiths’ 510(k) or any portions thereof, as
applicable, for purposes of including it in a 510(k) submission for a cartridge developed by or for RareGen, (vii) a license to
any relevant intellectual property associated with Smiths’ cartridge, (viii) a letter of support for a cartridge developed
by or for RareGen that could be sent to a regulatory authority (including the FDA), (ix) an agreement that Smiths will not disparage
any cartridge developed by or for RareGen, (x) a commitment that, assuming a cartridge developed by or for RareGen meets Smiths’
specifications, Smiths will communicate to customers and the market that the cartridge developed by or for RareGen is compatible
with Smiths’ pumps and appropriate for use for the treatment of pulmonary arterial hypertension, (xi) a commitment from Smiths
that Smiths will support the refurbishment and maintenance of pumps that are available for use with Sandoz’s treprostinil
product, and (xii) a commitment that Smiths will continue to supply all other disposables and consumables necessary for use with
pumps that are available for use with Sandoz’s treprostinil product.

 

    3

     

    

 

“New Counsel”
means any substitute or additional legal counsel engaged by RareGen (and, if applicable, Holdings) with respect to the Claims
or the Litigation.

 

“Order”
means any order, judgment, ruling, injunction, award, decree or writ of any Governmental Authority.

 

“Parties”
shall have the meaning assigned to such term in the introduction to this Agreement.

 

“Person”
means any natural person, corporation, partnership, limited liability company, joint stock company, joint venture, association,
company, estate, trust or other organization, whether or not a legal entity, custodian, trustee, executor, administrator, nominee
or entity in a representative capacity and any Governmental Authority.

 

“Proceeds”
shall have the meaning assigned to such term in the UCC.

 

“Promotion
Agreement” means that certain Promotion Agreement, dated as of August 1, 2018, by and between Counterparty and Sandoz,
the First Amendment thereto dated May 8, 2020, and any amendments or modifications to the foregoing.

 

“Protective
Order” means a stipulated order to protect confidential information prepared by the parties to the Litigation and ordered
by the Court.

 

“RareGen”
shall have the meaning assigned to such term in the introduction to this Agreement.

 

“Recipient”
means the Party to this Agreement receiving Confidential Information from the Disclosing Party.

 

“Records”
shall have the meaning assigned to such term in the UCC.

 

“Sandoz”
means Sandoz Inc.

 

“Secured Obligations”
means, collectively: (a) the prompt payment by RareGen, as and when due, of the Holdings’ Share to Holdings and the due performance
by RareGen of all of its obligations in respect of the Transaction Documents, (b) all other debts, liabilities, obligations, covenants
and duties of RareGen owing to Holdings now or hereafter existing, whether direct or indirect, absolute or contingent or due or
to become due, arising under or in connection with the Transaction Documents or any of the transactions contemplated thereby and
including any interest due thereon and all fees, costs and expenses incurred by Holdings in connection therewith; (c) all debts,
liabilities, obligations, covenants and duties of RareGen to pay or reimburse Holdings for all expenses, including attorneys’
fees, incurred by Holdings in connection with the enforcement, attempted enforcement or preservation of any rights or remedies
under the Transaction Documents, including all such costs and expenses incurred during any legal proceeding, including any proceeding
under any applicable bankruptcy, insolvency or other similar debtor relief laws; and (d) all interest and fees on any of the foregoing,
whether accruing prior to or after the commencement by or against RareGen of any proceeding under any applicable bankruptcy, insolvency
or other similar debtor relief laws naming RareGen as the debtor in such proceeding, regardless of whether such interest and fees
are allowed claims in such proceeding.

 

“Senior Funder”
means Henderson SPV, LLC, a Delaware limited liability company.

 

“Senior Funder
Agreement” means that certain Financing Agreement, dated June 4, 2020, by and between RareGen and Senior Funder.

 

    4

     

    

 

“Settlement”
means any compromise, discontinuance, waiver, payment, release or other form of settlement whatsoever where value passes from or
on behalf of one or more Defendants to or for the benefit of RareGen or any of RareGen’s Affiliates in circumstances in which
any of the Litigation does not commence or continue as a result of or in connection with the passing of that value; and “Settle”,
“Settles” and “Settled” have corresponding meanings.

 

“Smiths”
means Smiths Medical ASD, Inc.

 

“Taxes”
means any and all applicable taxes, duties, charges or levies of any nature imposed by any taxing or other Governmental Authority,
including income, gains, capital gains, surtax, capital, franchise, capital stock, value-added taxes, taxes required to be deducted
from payments made by the payor and accounted for to any tax authority, employees’ income withholding, back-up withholding,
withholding on payments to foreign Persons, social security, national insurance, unemployment, worker’s compensation, payroll,
disability, real property, personal property, sales, use, goods and services or other commodity taxes, business, occupancy, excise,
customs and import duties, transfer, stamp and other taxes (including interest, penalties or additions to tax in respect of the
foregoing), and includes all taxes payable pursuant to any provision of state, local or foreign law.

 

“Total Deployments”
shall have the meaning assigned to such term in Section 2.1.

 

“Transaction
Documents” means, collectively, this Agreement and any other agreement, document or instrument contemplated hereby or
delivered in connection herewith or therewith, including any instruction letter with Counsel, but for purposes of clarity, excluding
the Agreement and Plan of Merger, by and among the Liquidia Corporation, a Delaware corporation, Liquidia Technologies, Inc., a
Delaware corporation, RareGen, Gemini Merger Sub I, Inc., a Delaware corporation, Gemini Merger Sub II, LLC, a Delaware limited
liability company, and Holdings (the “Merger Agreement”), and any other agreement, document or instrument (other
than this Agreement) delivered in connection with the Merger Agreement.

 

“UCC”
means the Uniform Commercial Code as in effect on the date hereof in the State of Delaware or, in relation to the perfection or
priority of a security interest, the Uniform Commercial Code that then governs under the choice of law rules applicable to questions
of perfection or priority.

 

“United Therapeutics”
means United Therapeutics Corporation.

 

ARTICLE II

TERMS OF FINANCING

 

2.1              
Deployments. Subject to the terms and conditions of this Agreement (including Section 2.2), Holdings commits
to make payments to RareGen or on RareGen’s behalf (each payment, a “Deployment”, and the total of such
payments, the “Total Deployments”), at any time and from time to time from the date of this Agreement, to be
used by RareGen exclusively for the payment of Counsel Fees and Litigation Expenses. In consideration of the foregoing, the Parties
hereby agree that Holdings is entitled to Holdings’ Share, free and clear of any Encumbrance.

 

2.2              
Funding by Senior Funder. The Parties acknowledge and agree that RareGen shall first seek to have its Counsel Fees
and Litigation Expenses funded by Senior Funder pursuant to the Senior Funder Agreement. Holdings’ obligation to pay Counsel
Fees and Litigation Expenses pursuant to Section 2.1 shall be applicable only if (i) Senior Funder has no obligation to fund such
Counsel Fees or Litigation Expenses pursuant to the Senior Funder Agreement, (ii) Senior Funder otherwise fails to fund such amounts
within thirty (30) days of the date on which Senior Funder is required to fund such amounts in accordance with the Senior Funder
Agreement, (iii) the Senior Funder Agreement is terminated or otherwise rendered non-operable by failure of either party thereto
or by operation of law, or (iv) the Senior Funder’s obligations under the Senior Funding Agreement are exhausted or otherwise
extinguished.

 

    5

     

    

 

2.3              
Deployment Procedure. No more than once per calendar month, RareGen may submit a written request (a “Deployment
Request”) to Holdings for each desired Deployment. Holdings shall disburse such Deployment to RareGen or the ultimate
payee on RareGen’s behalf; provided that:

 

(a)               
RareGen provides documentation evidencing either (i) that Senior Funder is not obligated to fund such amounts pursuant to
the Senior Funder Agreement or (ii) RareGen’s commercially reasonable attempt to have such amounts funded by Senior Funder
in accordance with the terms of the Senior Funder Agreement and Senior Funder’s failure or refusal to do so.

 

(b)               
RareGen provides an invoice detailing the out-of-pocket costs and fees incurred by RareGen and not funded by Senior Funder
pursuant to the Senior Funder Agreement in accordance with the uses permitted under Section 2.1, which invoice will be in
form and substance reasonably acceptable to Holdings and which costs and fees were not paid by a previous Deployment, along with
invoices or other documentation reasonably acceptable to Holdings to substantiate said costs and fees; and

 

(c)               
No breach or default by RareGen exists, and remains uncured, under any of the Transaction Documents as of the date of such
request or the funding of the related Deployment (it being understood that if a request is made at the time that a breach or default
by RareGen exists, RareGen may re-make the request at such time as such breach or default has been cured).

 

Subject to the terms
of this Agreement, within fifteen (15) Business Days of Holdings’ receipt of the Deployment Request, Holdings shall disburse
the Deployment in immediately available funds to or on behalf of RareGen as directed by RareGen in the Deployment Request.

 

ARTICLE III

DISTRIBUTION OF LITIGATION PROCEEDS

 

3.1              
Priority of Payment. RareGen will immediately notify Holdings of its receipt of any Litigation Proceeds (whether
by Counsel or Sandoz for RareGen’s account or otherwise). Within fifteen (15) days of RareGen (or Counsel) receiving any
Litigation Proceeds, RareGen will (i) pay (or cause to be paid) to Senior Funder that portion of the Litigation Proceeds to which
Senior Funder is entitled pursuant to the Senior Funder Agreement, and (ii) pay (or cause to be paid) any remaining Litigation
Proceeds to Holdings as the Holdings’ Share (or a portion thereof) in immediately available funds in accordance with wire
instructions to be provided to RareGen by Holdings. All Litigation Proceeds payable to Holdings will first be applied to the repayment
of the Total Deployments, and thereafter to the remainder of the Holdings’ Share.

 

3.2              
Lockbox Account. In the event that RareGen is required under the Senior Funder Agreement to pay any Litigation Proceeds
into a lockbox account, escrow account or other similar restricted account, then Holdings agrees that no portion of such Litigation
Proceeds shall become payable to Holdings pursuant to this Agreement unless and until such funds are released to RareGen from such
lockbox account, escrow account or other restricted account pursuant to the Senior Funder Agreement.

 

3.3              
Maturity Date. Subject to Section 3.4, Holdings’ Share, to the extent not previously paid in accordance
with Section 3.1 or Section 3.2, shall become due and payable, and RareGen shall pay Holdings’ Share in cash
to Holdings, on December 31, 2023 (the “Maturity Date”); provided that if, as of such date, any of the
requirements set forth in (a) through (c) below have not been satisfied, then the Maturity Date shall be extended automatically
for consecutive one (1) calendar year periods thereafter until the first such date to occur following the satisfaction of all
requirements set forth in (a) through (c) below.

 

    6

     

    

 

(a)               
Final Resolution has occurred.

 

(b)               
Each of RareGen and Holdings has complied with all of its obligations pursuant to this Agreement.

 

(c)               
All Litigation Proceeds (if any) have been disbursed in accordance with this Agreement.

 

3.4              
Non-Recourse. If there are no Litigation Proceeds (after deducting any amounts payable to the Senior Funder pursuant
to the Senior Funder Agreement), then no amount shall be payable to Holdings under Section 3.1, Section 3.2 or Section
3.3, and if there are Litigation Proceeds but they are less (after deducting any amounts payable to the Senior Funder pursuant
to the Senior Funder Agreement) than the amount necessary to pay Holdings the entirety of Holdings’ Share, RareGen shall
not be obligated to pay the difference to Holdings.

 

3.5              
Tax Matters.

 

(a)               
RareGen and its successors are liable for and shall pay any and all Taxes (other than Taxes imposed upon Holdings as a consequence
of Holdings’ income) imposed in connection with, or as a result of, the Litigation Proceeds or as a consequence of any Settlement
or Business Deal. If, however, (i) the aggregate taxable income of or on account of RareGen or its successors from the receipt
of, or entitlement to, the Litigation Proceeds, exceeds (ii) the aggregate income tax deductions available to or on account of
RareGen or its successors, whether in the same tax year in which any such Litigation Proceeds are accrued or received or in any
other tax year, in connection with its payment of expenses associated with the conduct of the Litigation and for the requirement
to pay, or payment of, the Litigation Proceeds to Senior Funder and Holdings (such excess being referred to herein as the “Mismatch
Amount”), then any Litigation Proceeds otherwise payable to Holdings hereunder shall be reduced by an amount sufficient
for the payment or offset of any income taxes payable or the reduction of any deferred tax asset resulting from such Mismatch Amount.
For purposes of the preceding sentence, the amount of the reduction of any deferred tax asset shall be measured in accordance with
generally accepted accounting principles.

 

(b)               
Other than as provided for in Section 3.5(a), no Tax payment, liability or obligation of RareGen shall operate to reduce
any amount payable to Holdings under this Agreement. If any such reduction or withholding is required by law, RareGen shall (i)
promptly notify Holdings upon becoming aware of the required deduction or withholding; (ii) pay to the relevant authorities (within
the time allowed) the full amount required to be deducted or withheld (including the full amount required to be deducted or withheld
from any additional amount paid by RareGen to Holdings under this clause); (iii) promptly provide Holdings an official receipt
(or a certified copy or such other evidence reasonably acceptable to Holdings) evidencing the relevant withholding and payment
to such authorities; and (iv) pay to Holdings such amounts remaining after making any such withholdings or deductions.

 

(c)               
This Agreement shall not, in whole or in part, be deemed to create or imply a partnership for federal or state or local
income tax purposes, and neither Holdings nor RareGen will take any action or make any election to treat their relationship as
a partnership for income tax purposes.

 

3.6               Interest
On Overdue Amounts. If RareGen fails to pay (or cause to be paid) any amounts due or owed to Holdings on the date when
due, including any failure to instruct Counsel to disburse any amount to Holdings in accordance with the terms of this
Agreement, RareGen shall thereafter pay to Holdings interest on such amount for the period from and including the date due,
to but excluding the date on which such amount is paid in full, at a rate per annum (computed on the basis of the actual days
elapsed) equal to the Default Rate.

 

    7

     

    

 

ARTICLE IV

SETTLEMENT

 

4.1              
Right to Settle. Subject to the provisions of this Article IV, (i) RareGen shall Settle any Claim or Claims
or all or any portion of the Litigation with one or more Defendants at such times and upon such terms as Holdings may direct, in
Holdings’ sole but reasonable discretion; provided, however, that RareGen shall not be required to enter into any such Settlement
if the terms thereof would lead to liability or the creation of a financial or other obligation or restriction on the part of RareGen,
Liquidia Corporation or Liquidia Technologies, Inc. (other than a covenant not to sue or other similar obligation customarily included
in a settlement agreement and related to the subject matter of the Litigation), and (ii) RareGen shall not Settle any Claim or
Claims or all or any portion of the Litigation without the prior written consent of Holdings. In connection with any such Settlement,
RareGen will sign such releases and waivers as may be customary in a settlement of claims.

 

4.2              
Communication of Settlement Offers. Subject to and pursuant to any applicable Protective Order and subject to the
provisions of this Article IV, each of RareGen and Holdings shall promptly upon and after its receipt or knowledge of any
Settlement offer, demand or proposal (but in no event later than two Business Days after its receipt or knowledge thereof), communicate
to the other party all such Settlement offers, demands and proposals, and the substance of all Settlement discussions and provide
copies of any related documents. If a Settlement offer, demand or proposal is not made or received in writing, the party receiving
such Settlement offer, demand or proposal shall promptly upon and after its receipt or knowledge thereof (but in no event later
than two Business Days after its receipt or knowledge of the offer, demand or proposal) provide the other party with a verbal summary
of all provisions of the Settlement offer, demand or proposal.

 

4.3              
Settlement Agreement. Subject to and pursuant to any applicable Protective Order and subject to the provisions of
this Article IV, each of RareGen and Holdings shall provide to the other true, correct and complete copies of all fully
executed Settlement documents, any amendments or modifications thereto, and subsequent documents relating to the collection or
payment of the Litigation Proceeds.

 

ARTICLE V

LITIGATION MANAGEMENT

 

5.1              
Control of the Litigation. As between them, RareGen agrees that Holdings shall have the sole and exclusive right
to control, act or refrain from acting in respect of any act, request or decision in connection with the Litigation; provided
that (i) Holdings shall consult with RareGen as it relates to, and keep RareGen informed of, any and all aspects of the Litigation
and consider the input of RareGen with respect to any decisions Holdings makes regarding the Litigation, and (ii) none of the
foregoing shall require Holdings to continue the Litigation to the extent Holdings reasonably determines that the Litigation no
longer has merit. In furtherance thereof, RareGen shall (and shall instruct Counsel to) (A) communicate directly with Holdings
with respect to the Litigation and provide Holdings with (i) written or email notice upon the occurrence of any material events
in the Litigation, and (ii) a status update by conference call at other times upon Holdings’ reasonable request, and (B)
take such actions (or refrain from taking such actions) with respect to the Litigation as may be directed by Holdings, in its
reasonable good faith determination, from time to time. RareGen shall cooperate with Holdings in all reasonable respects in connection
with the conduct of the Litigation and pursuit of the Claims, including making available records relating to the Litigation or
that must be produced in the Litigation and furnishing to Holdings, employees of RareGen and its Affiliates as may be reasonably
necessary for the conduct of the Litigation and to pursue the Claims; provided, however, that Holdings shall reimburse RareGen
for any and all actual and reasonable costs and out-of-pocket expenses (in each case, without any mark-up) associated with the
furnishing of services by employees and consultants of RareGen and its Affiliates at the request of Holdings or as reasonably
required by law, regulation, rule or to satisfy a requirement of the court or the Litigation. For purposes of the preceding sentence,
(i) Holdings shall not be required to reimburse RareGen for any time spent by employees or consultants of RareGen or its Affiliates
in monitoring the Litigation, and (ii) for time spent by employees of RareGen and its Affiliates that will be reimbursed by Holdings,
time will be billed in quarter hour increments at a rate equal to the applicable employee’s annual base salary plus benefits
divided by 2,000 (or, with respect to a part-time employee, the number of hours such employee is scheduled to work on an annual
basis).

 

    8

     

    

 

5.2              
Counsel.

 

(a)               
RareGen shall continue to retain Current Counsel, and shall not retain New Counsel, with respect to the Litigation unless
otherwise directed by Holdings. In the event Holdings desires to retain New Counsel, Holdings agrees to notify RareGen in writing
of such proposed New Counsel and to consult with RareGen prior to retaining such New Counsel, including with respect to the economic
terms of engagement and any engagement agreement or letter to be entered into. Upon entering into any such engagement at Holdings’
direction, RareGen shall provide Holdings with a copy of the engagement agreement or letter entered into with such New Counsel.
RareGen and Holdings agree that RareGen does not waive any current or future conflicts of interest with Current Counsel or New
Counsel who may be retained and Holdings agrees that any such conflict of interest will be grounds for the immediate termination
of counsel unless RareGen expressly waives any such conflict in writing, which waiver shall be granted unless such conflict relates
to the same or a substantially related matter to those at issue in the Litigation.

 

(b)               
At the request of Holdings, RareGen shall agree that its Counsel shall jointly represent RareGen and Holdings and agree
to allow its Counsel to communicate directly with Holdings regarding the Litigation and take direction in the conduct of the Litigation
directly from Holdings; provided, however, that, in such event, Holdings shall (and shall instruct Counsel to) communicate with
RareGen and provide (or instruct Counsel to provide) RareGen with such information as RareGen would be obligated to provide to
Holdings pursuant to this Article V and Article VI in the absence of such joint representation. In connection with any joint representation
of RareGen and Holdings by Counsel, RareGen (and, if applicable, its Affiliates) shall execute such conflict waivers and joint
prosecution agreements as may be reasonably requested by Holdings or such Counsel. For clarity, RareGen counsel shall remain involved
in the Litigation with insight and review into all matters in the Litigation and the right to request changes to aspects of the
Litigation that might interfere with RareGen’s business outside the scope of the Litigation, which requests shall be considered
in good faith by Holdings.

 

5.3              
Engagement Agreements. Neither RareGen nor Holdings shall enter into any new Engagement Agreements or amend, modify
or waive any provision in any Engagement Agreements without the other party’s prior written consent; provided, however, that
RareGen’s consent to any such new Engagement Agreement or amendment, modification or waiver shall not be unreasonably withheld.

 

5.4              
Promotion Agreement. RareGen shall not terminate, amend, modify or waive any provision in the Promotion Agreement
that could reasonably be expected to affect the Litigation or the division or collection of any Litigation Proceeds without Holdings’
prior written consent.

 

5.5              
Senior Funder Agreement. RareGen shall not terminate, amend, modify or waive any provision in the Senior Funder Agreement
without Holdings’ prior written consent. RareGen shall comply in all material respects with respect to its obligations under
the Senior Funder Agreement.

 

    9

     

    

 

5.6              
 Conduct of the Litigation. RareGen shall use commercially reasonable efforts to, at the Senior Funder’s and
Holdings’ sole expense (as set forth in Article II), (a) diligently pursue the Claims and the Litigation as directed by
Holdings; (b) collect all Litigation Proceeds awarded or agreed upon as soon as practicable, including pursuing the enforcement
of any final, non-appealable judgment or award as soon as possible as directed by Holdings; (c) enforce all of RareGen’s
rights in connection with the Promotion Agreement and the Senior Funder Agreement, and promptly enter any judgment obtained in
connection therewith in all appropriate jurisdictions as directed by Holdings; and (d) take all actions necessary in connection
with the foregoing.

 

ARTICLE VI

LITIGATION INFORMATION; CONFIDENTIALITY

 

6.1              
Communication of Litigation Information.

 

(a)               
Information. Subject to Section 6.1(b) and any applicable Protective Order, during the Litigation, RareGen
shall (and shall instruct Counsel to) forward to Holdings copies of all briefs, motions and final orders related to the Litigation
within two Business Days of RareGen’s receipt or submission thereof. Copies of all briefs, motions and final orders forwarded
to Holdings shall be subject to the restrictions placed on such materials by any and all applicable Protective Orders that may
be in place in the Litigation at the time of the forwarding thereof.

 

(b)               
Privileged Information. RareGen and Holdings acknowledge and agree that, as a result of their discussions leading
up to, and the execution and performance of, the Transaction Documents, they have shared and continue to share a common interest
privilege in information subject to the attorney work-product doctrine and documents relevant to the Litigation, which information
and documents shall be deemed to be Confidential Information. Notwithstanding anything to the contrary contained herein, (i) RareGen
has not and will not deliver any attorney-client privileged information to Holdings, (ii) RareGen has not and will not waive attorney-client
privilege, and (iii) RareGen’s delivery obligations under this Article VI and the other applicable provisions of this
Agreement shall specifically exclude any information or document the delivery of which to Holdings, in the opinion of Counsel,
would waive the attorney-client privilege or result in a violation of a Protective Order.

 

6.2              
Confidentiality.

 

(a)               
Exclusive Ownership of Information by Disclosing Party. The Recipient agrees and acknowledges that all Confidential
Information provided to it is and shall remain at all times the exclusive property of and owned by the Disclosing Party, and that
the Recipient’s use or awareness of such Confidential Information shall create no rights, at law or in equity, in the Recipient
in or to such Confidential Information, or any aspect or embodiment thereof. The furnishing of any Confidential Information hereunder
shall not constitute (i) a grant, whether express or by implication, estoppel or otherwise, of any ownership interest in or license
of any patent, trademark, service mark, business and trade secret or other proprietary right to such Confidential Information,
or of any right to use such Confidential Information for any purpose other than as specified in this Agreement or (ii) a waiver
of any attorney-client privilege or work product protection or any other applicable or available similar privilege or protection.

 

(b)               
Non-Disclosure of Information. The Recipient shall not for any reason disclose, use, reveal, report, publish, transfer
or make available, directly or indirectly, to any Person other than its representatives and Affiliates, any Confidential Information
provided to it except (i) when necessary to further RareGen’s or Holdings’ legal interests in connection with the
performance of its obligations or rights under this Agreement or the enforcement of its rights under this Agreement, (ii) as permitted
by the Disclosing Party, or (iii) as required by law. Notwithstanding anything in this Section 6.2(b) to the contrary,
Recipient shall not disclose any information that Recipient knows to be subject to a Protective Order.

 

    10

     

    

 

ARTICLE VII

TERMINATION OF AGREEMENT

 

7.1              
Termination. This Agreement commences on the date hereof and, except as provided in Section 7.2, shall terminate
at the time at which a Final Resolution has occurred, RareGen has complied with all of its obligations pursuant to this Agreement,
and all Litigation Proceeds (if any) have been disbursed in accordance with this Agreement. In addition, in the event (a) (i) Holdings
should breach or otherwise fail to satisfy any payment obligation set forth in this Agreement, provided such failure to pay is
not subject to a good faith dispute between Holdings and RareGen, (ii) such breach or failure to perform is not a result of RareGen’s
negligence or bad faith, and (iii) such breach or failure to perform shall not have been cured within thirty (30) days following
receipt by Holdings of written notice of such breach or failure from RareGen (except in the case of a breach or failure that is
not curable or Holdings has ceased to exercise commercially reasonable efforts to cure such breach or failure, in which event such
termination shall be effective upon notice of termination by RareGen), or (b) Holdings files any petition or action for relief
under any bankruptcy, reorganization, insolvency or moratorium law, or any involuntary petition is filed against Holdings (unless
such petition is dismissed or discharged within thirty (30) days) under any bankruptcy statute now or hereafter in effect, or a
custodian, receiver, trustee, assignee for the benefit of creditors is appointed to take possession, custody or control of any
property of Holdings, then, at any time (but in the case of subsection (a), only while such breach or failure remains uncured),
RareGen shall have the right, in its sole discretion and without the prior consent of Holdings, to enter into a Settlement, withdraw
from the Litigation or otherwise cause the Litigation to be dismissed.

 

7.2              
Consequences of Termination. The provisions of Sections 3.4, 6.2, and Articles I, VII,
VIII, X, XI and XII shall survive termination of this Agreement. Without limiting the foregoing, (a)
Holdings shall be entitled, in order to protect its own interest in relation to this Agreement, to keep copies of the Confidential
Information provided to it pursuant to this Agreement, subject to Holdings’ ongoing obligations pursuant to Section 6.2;
and (b) any rights or obligations accrued prior to the date of termination of this Agreement (including with respect to breaches
of this Agreement) shall survive termination.

 

7.3              
Clawback. In the event any payment to Holdings made under this Agreement must be returned or disgorged by Holdings
as a result of a legal proceeding against RareGen or its Affiliates, including an insolvency proceeding or fraudulent conveyance
proceeding against RareGen or its Affiliates, the right of Holdings to such payment shall be reinstated to the maximum extent permitted
by law and Holdings shall have the right to recover such reinstated amount from Litigation Proceeds or, subject to the terms and
conditions of this Agreement, from RareGen.

 

ARTICLE VIII

INDEMNIFICATION

 

8.1              
Holdings Indemnity. Holdings shall indemnify, defend and hold RareGen (and RareGen’s Affiliates, officers,
managers, directors, partners, equityholders, employees, permitted assigns, participants, attorneys and agents) harmless from any
liability, claim, loss, judgment, damage, cost or expense, including all fees, costs and expenses of enforcement of the Transaction
Documents (including legal fees, costs and expenses) that are incurred in connection with (i) any claim of Defendants or any other
party against RareGen (or RareGen’s Affiliates, officers, managers, directors, partners, equityholders, employees, permitted
assigns, participants, attorneys and agents) in connection with or resulting in any way from the Claims or the Litigation, or (ii)
any breach by Holdings of any of the terms of this Agreement.

 

    11

     

    

 

8.2              
 RareGen Indemnity. RareGen shall indemnify, defend and hold Holdings (and Holdings’ officers, managers, directors,
partners, equityholders, employees, permitted assigns, participants, attorneys and agents) harmless from any liability, claim,
loss, judgment, damage, cost or expense, including all fees, costs and expenses of enforcement of the Transaction Documents (including
legal fees, costs and expenses) that are incurred in connection with any breach by RareGen of any of the terms of this Agreement.

 

ARTICLE IX

SECURITY AGREEMENT

 

9.1              
Grant of Security Interest. As security for the payment, performance and observance in full of all of the Secured
Obligations, RareGen hereby grants, assigns and pledges to Holdings, its successors, agents, designees and assigns, a continuing
security interest, in any and all right, title or interest of RareGen in or to any and all of the following assets, rights and
properties now owned or at any time hereafter acquired by RareGen or in which RareGen now has or at any time in the future may
acquire any right, title or interest (collectively, the “Collateral”):

 

(a)               
the Litigation Proceeds;

 

(b)               
the Claims;

 

(c)               
RareGen’s rights under the Promotion Agreement and the Senior Funder Agreement to receive Litigation Proceeds;

 

(d)               
a copy of RareGen’s books, Records, files, correspondence, evidentiary materials and records pertaining to the Claims;

 

(e)               
rights under any appeal bond or similar instrument posted by any of the Defendants in the Litigation; and

 

(f)                
to the extent not otherwise included, all Proceeds of any and all of the foregoing.

 

9.2              
Continuing Security Interest. RareGen acknowledges and agrees that the security interest of Holdings in the Collateral
constitutes continuing collateral security for all of the Secured Obligations and shall remain in full force and effect until RareGen
has performed all of its obligations under the Transaction Documents in full, including payment of the Secured Obligations.

 

9.3              
Financing Statements. RareGen hereby irrevocably authorizes Holdings at any time and from time to time to file in
any filing office in any jurisdiction that Holdings deems advisable (a) any UCC financing statement providing the name of RareGen
as debtor, Holdings or its designee as secured party and indicating the Collateral (or all assets of RareGen) as collateral covered
by the financing statement and (b) any other notice, filing or other document that Holdings deems necessary or advisable to perfect
or protect the security interest or to maintain its first priority.

 

9.4              
Covenants. So long as any of the Secured Obligations shall remain unpaid or unsatisfied, RareGen shall:

 

(a)               
preserve and maintain its existence, rights, franchises and privileges in the jurisdiction of its organization, and will
qualify and remain qualified in good standing in each jurisdiction where failure to preserve and maintain such existence, rights,
franchises, privileges and qualification could reasonably be expected to have an adverse effect on the Litigation, RareGen’s
financial condition or the collection of any Litigation Proceeds;

 

    12

     

    

 

(b)               
 at its own cost and expense, take such action and execute, acknowledge and deliver such agreements, instruments or other
documents as Holdings may from time to time reasonably require in order (i) to perfect and protect or maintain the perfection of
the security interest in the Collateral and (ii) to enable Holdings to enforce its rights in respect of the Collateral in accordance
with the terms hereof;

 

(c)               
do all things reasonably necessary at the written request of Holdings so that Holdings will have a perfected security interest
in RareGen’s share of any judgment obtained in the Litigation, subordinated only to any security interest of Senior Funder
in the Collateral, and to establish Holdings’ priority in RareGen’s share of any judgment obtained in the Litigation
under applicable procedural law or court rules;

 

(d)               
at its own cost and expense, take any and all actions necessary to defend its title to the Collateral against all parties
and to defend the security interest of Holdings in the Collateral and the priority thereof against any Encumbrance or security
interest (other than any security interest of Senior Funder in the Collateral);

 

(e)               
not cease operations, liquidate or dissolve;

 

(f)                
not merge or consolidate with any other Person without notifying Holdings thereof within three (3) Business Days of the
closing of such merger or consolidation;

 

(g)               
not change its name unless RareGen shall have given Holdings at least thirty (30) days’ prior written notice of the
change;

 

(h)               
ensure that Holdings has a second priority right in and to the Litigation Proceeds, subordinated only to the interests of
Senior Funder in the Litigation Proceeds;

 

(i)                
not (i) assign or transfer any interest in the Collateral, (ii) make any sale lease or other disposition of any of the Collateral,
(iii) license any of the Collateral or (iv) grant or permit to exist any claims, Encumbrances or security interests (voluntary
or involuntary) in or on the Collateral other than as set forth in the Senior Funder Agreement;

 

(j)                
comply in all material respects with applicable laws and regulations and all Orders applicable to it where failure to comply
could reasonably be expected to have an adverse effect on the Litigation, RareGen’s financial condition or the collection
of any Litigation Proceeds; and

 

(k)               
pay and discharge as the same shall become due and payable, all of its obligations and liabilities (except any such amounts
that are disputed in good faith by RareGen), including (i) all Tax liabilities, assessments and governmental charges or levies
upon it or its properties or assets, unless the same are being contested in good faith by appropriate proceedings reasonably diligently
conducted, (ii) all lawful claims that, if unpaid, would by law become an Encumbrance not permitted hereunder; and (iii) all debt,
as and when due and payable.

 

9.5              
Remedies and Applications of Proceeds.

 

(a)               
If RareGen fails to pay or perform any of the Secured Obligations when due to be paid or performed, the failure shall constitute
a default under this Agreement for the purposes of Part 6 of Article 9 of the UCC and Holdings shall have, in addition to all other
rights and remedies granted to it in this Agreement and the other Transaction Documents, all rights and remedies of a secured party
under the UCC and other applicable law.

 

    13

     

    

 

(b)               
 The cash proceeds actually received from the sale or other disposition or collection of Collateral may be applied to the
expenses of the sale or other disposition or collection, including to the reimbursement of legal fees and expenses of Holdings.
After such application, any cash proceeds resulting from the sale or other disposition or collection shall be paid to Holdings
until Holdings has received an amount equal to the Secured Obligations.

 

9.6              
Certain Waivers. RareGen waives, to the fullest extent permitted by applicable law:

 

(a)               
except for the exercise of reasonable care in the custody of any Collateral in its possession and the accounting for moneys
actually received by it hereunder, any duty of Holdings as to the preservation of any Collateral or as to the taking of any necessary
steps to preserve rights against prior parties or any other rights pertaining to any Collateral;

 

(b)               
any right to require Holdings to marshal any of the Collateral or other collateral or security for any of the Secured Obligations;
and

 

(c)               
any right to require Holdings (i) to proceed against any party, (ii) to exhaust any other collateral or security for any
of the Secured Obligations, (iii) to pursue any remedy to the exclusion of any other remedy, or (iv) to make or give any presentments,
demands for performance, notices of nonperformance, protests, notices of protests or notices of dishonor in connection with any
of the Collateral.

 

9.7              
Attorney-in-Fact. RareGen hereby appoints Holdings as RareGen’s attorney-in-fact to do all things in RareGen’s
name and on RareGen’s behalf in connection with Holdings’ exercise of its rights and remedies under and in accordance
with the Transaction Documents, including making any court filings required pursuant to Section 9.4(c). If this Section
9.7, or the application thereof, is or becomes invalid or unenforceable with respect to any circumstance, the application of
this Section 9.7 to any other circumstance shall not be affected and shall remain valid and be enforceable to the full extent
permitted by applicable Law.

 

9.8              
Subordination to Senior Funder. The rights of Holdings hereunder and all of the Secured Obligations are hereby, and
shall continue to be, subject and subordinate in priority and payment to the rights of Senior Funder under the Senior Funder Agreement
and to all sums due or to become due to Senior Funder under the Senior Funder Agreement; provided that Holdings is not in any way
restricted from enforcing its rights under Articles IV, V and VI hereof. Holdings agrees that so long as any sum is owed to Senior
Funder pursuant to the Senior Funder Agreement, Holdings shall not receive or retain payments of from RareGen pursuant to this
Agreement. If Holdings shall receive any such payments pursuant to this Agreement or any cash distributions in respect of, or other
proceeds of, the Collateral in excess of what Holdings is entitled to pursuant to this Agreement (including this Section 9.8),
Holdings shall hold the same in trust, as trustee, for the benefit of Senior Funder and shall promptly deliver the same to or at
the direction of Senior Funder for the benefit of Senior Funder in precisely the form received (except for the endorsement or assignment
thereof by Holdings without recourse or warranty), it being understood that it is the intention of the parties that until Senior
Funder has been paid the amounts to which it is entitled pursuant to the Senior Funder Agreement in full, Senior Funder shall receive
all payments and cash distributions of Litigation Proceeds from RareGen and all proceeds relating to any realization upon, distribution
in respect of or interest in any of the Collateral as and to the extent set forth in the Senior Funder Agreement.

 

    14

     

    

 

ARTICLE X

GOVERNING LAW; JURISDICTION AND VENUE; DISPUTES

 

10.1          
Governing Law. This Agreement and the transactions contemplated hereby shall be governed by and construed in accordance
with the laws of the State of Delaware applicable to contracts entered into and fully to be performed in such state. Conflict
of laws rules that would require the application of the law of any other jurisdiction shall not apply.

 

10.2          
Arbitration of Disputes.

 

(a)               
All disputes, claims or causes of action between the Parties arising out of or relating to the Transaction Documents and
the transactions contemplated thereby shall be resolved in accordance with this Section 10.2.

 

(b)               
All disputes between the Parties shall be resolved solely and exclusively, to the fullest extent permitted by law, by final,
binding and confidential arbitration in Washington, D.C. The arbitration shall be administered by and in accordance with the then
existing Rules of Practice and Procedure of Judicial Arbitration & Mediation Services, Inc. (JAMS), or its successor entity.
Any awards or orders in such arbitrations may be entered and enforced as judgments in federal courts of competent jurisdiction.

 

(c)               
The appointed arbitrator shall apply the laws of the State of Delaware applicable to contracts entered into and fully to
be performed in such state for purposes of determining any dispute.

 

(d)               
By agreeing to these arbitration procedures, the Parties waive the right to resolve any such dispute through a trial by
jury or judge or by administrative proceeding. The arbitrator shall (i) have the authority to compel adequate discovery for the
resolution of the dispute and to award such relief as would otherwise be permitted by law; and (ii) issue a written arbitration
decision, including the arbitrator’s essential findings and conclusions and a statement of the award. The arbitrator shall
be authorized to determine if an issue is subject to this arbitration obligation and to award any and all remedies that either
Party would be entitled to seek in a court of law.

 

(e)               
The prevailing Party in such arbitration shall be entitled to receive reimbursement from the other Party of the prevailing
party’s reasonable legal fees, costs and disbursements in connection with such arbitration.

 

(f)                
The Parties shall have the right to seek specific performance or equitable relief in arbitration pursuant to this Section
10.2.

 

ARTICLE XI

NOTICES

 

11.1        
Method. All notices, reports, records or other communications that are required or permitted to be given to the Parties
under this Agreement shall be sufficient in all respects if given in writing and delivered in person, by electronic mail (if receipt
is confirmed, electronically or otherwise), by overnight courier, or by registered or certified mail, postage prepaid, return receipt
requested, to the receiving Party at the following address(es) for such Party or such other address(es) as such Party may have
given to the other Party pursuant to this Section 11.1:

 

	If to RareGen:	RareGen, LLC
	 	P.O. Box 110085
	 	Research Triangle Park, NC 27709
	 	Attn: Neal Fowler
	 	E-mail: Neal.Fowler@liquidia.com

 

    15

     

    

 

	If to Holdings:	PBM RG Holdings, LLC
	 	200 Garrett Street, Suite S
	 	Charlottesville, VA 22902
	 	Attn: General Counsel
	 	E-mail: legal@pbmcap.com

 

11.2          
Receipt. Notice shall be deemed given on (a) the date such notice is personally delivered, (b) three days after the
mailing if sent by registered or certified mail, (c) one Business Day after the date of delivery to the overnight courier if sent
by overnight courier, or (d) the date such notice is transmitted by electronic mail, if such transmission is prior to 5:00 p.m.
Eastern time on a Business Day, or the next succeeding Business Day if such transmission is later.

 

ARTICLE XII

GENERAL

 

12.1          
Interpretation. Section headings in this Agreement are for convenience of reference only and shall not affect the
interpretation or construction of this Agreement. The Transaction Documents will be deemed to have been jointly drafted by the
Parties and no provision shall be interpreted or construed for or against either Party because such Party actually or purportedly
prepared or requested such provision, any other provision or the Transaction Documents as a whole. The singular includes the plural
in this Agreement and vice versa. All pronouns shall include the masculine, feminine or neuter thereof, wherever the context and
facts require such construction. Examples and words like “including” are deemed to mean “without limitation.”
All references in this Agreement to Articles and Sections are references to the relevant provisions of this Agreement.

 

12.2          
Merger Clause. This Agreement and the other agreements, documents or instruments contemplated hereby shall constitute
the entire agreement between the Parties, and shall supersede all prior agreements, understandings and negotiations between the
Parties with respect to the subject matter hereof.

 

12.3          
Assignment. This Agreement shall inure to the benefit of, and shall be binding upon, the Parties and their respective
successors, permitted assigns, and legal representatives. Neither this Agreement, nor any rights, interests, obligations and duties
arising hereunder, may be assigned or otherwise conveyed by RareGen or Holdings, directly or indirectly, without the express consent
in writing of the other Party.

 

12.4          
Third Party Beneficiaries. Except as provided in Article VIII, this Agreement is made solely and specifically
among and for the benefit of the Parties, and their respective successors and permitted assigns, and no other Person shall have
any rights, interests or claims hereunder or be entitled to any benefits under or on account of this Agreement as a third party
beneficiary or otherwise.

 

12.5          
Independent Parties. The Parties are independent contractors to one another with respect to the Transaction Documents
and neither Party shall be deemed to be an agent, employee or joint venturer of the other by virtue of the Transaction Documents.
Nothing in the Transaction Documents shall constitute RareGen and Holdings as partners or fiduciaries of one another. Neither Party
shall have any power, right or authority to bind the other to any obligation or liability, to assume or create any obligation or
liability or transact any business in the name or on behalf of the other, or make any promises or representations on behalf of
the other, except as expressly set forth herein.

 

12.6          Costs,
Expenses and Fees. Each party shall bear its own costs and expenses in connection with the transactions described herein.

 

    16

     

    

 

12.7          
Amendment; Waiver. This Agreement shall not be amended, and no term or provision of this Agreement may be waived,
except in writing signed by a duly authorized representative of each Party. No delay on the part of a Party in exercising any
right, power or remedy under this Agreement shall operate as a waiver thereof, and no single or partial exercise of any right,
power or remedy by a Party shall preclude any further exercise thereof.

 

12.8          
Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of
which shall constitute one and the same instrument. Signatures to this Agreement may be delivered by facsimile or other electronic
means and any copy so delivered shall be deemed to be an original.

 

12.9          
Severability. If any provision of this Agreement, or the application thereof to any Person or circumstances, is or
becomes invalid or unenforceable, the remaining provisions shall not be affected and each remaining provision shall remain valid
and be enforceable to the full extent permitted by applicable law.

 

12.10       
Further Assurances. Each party shall promptly execute all documents and do all things that the other Party from time
to time reasonably requires to effect, perfect or complete the provisions of this Agreement and any transaction contemplated hereby.

 

[Signature page follows]

 

    17

     

    

 

IN WITNESS WHEREOF,
this Financing Agreement has been executed by the undersigned as of the date first set forth above.

 

	 	PBM RG HOLDINGS, LLC
	 	By: PBM Capital Group, LLC, its manager
	 	 
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 	 
	 	 
	 	RAREGEN, LLC
	 	 
	 	 
	 	By:	 
	 	Name:	 
	 	Title:Exhibit 10.39

 

JOINT DEVELOPMENT AGREEMENT

 

THIS JOINT DEVELOPMENT
AGREEMENT (this “Agreement”) is made as of the 3rd day of May 2019 by and between RAREGEN, LLC (“RareGen”)
and Carelife USA Inc. (“Manufacturer” and, collectively with RareGen, the “Parties” and each a “Party”).

 

BACKGROUND AND RECITALS

 

A.       RareGen
wishes to develop medication cartridges for use with CADD-MS® 3 ambulatory infusion pumps (the “Cartridges”)
for use in delivering the generic drug treprostinil that is manufactured by or on behalf of Sandoz Inc. and promoted by RareGen
for treating patients with pulmonary arterial hypertension.

 

B.       RareGen
wishes to engage Manufacturer to perform certain development and manufacturing services in connection with the development of the
Cartridges.

 

C.       Manufacturer
wishes to supply to RareGen or third parties designated by RareGen, and RareGen desires to purchase from Manufacturer (or have
purchased from Manufacturer), finished Cartridges ready for commercial sale once the development has been completed.

 

NOW THEREFORE, the
parties hereto, intending to be legally bound, agree as follows:

 

1.                 
Definitions. The following terms as used herein shall have the following meanings whether used in the singular
or plural (some terms may be defined within sections to which they apply):

 

1.1.           
“Affiliate” shall mean, with respect to a Party, any person or entity directly or indirectly controlling, controlled
by, or under common control with such Party. For purposes of this definition, "control," when used with respect to any
specified person or entity, means the power to direct the management and policies of such person or entity, directly or indirectly,
whether through the ownership of voting securities, by contract or otherwise; and the terms "controlling" and "controlled"
have meanings correlative to the foregoing.

 

1.2.           
“Background Intellectual Property” shall mean the RareGen Background Intellectual Property and the Manufacturer
Background Intellectual Property.

 

1.3.           
“Background Technology” shall mean the RareGen Background Technology and the Manufacturer Background Technology.

 

1.4.           
 “Manufacturer Background Intellectual Property” shall mean all patents, patent applications, copyrights or
trademarks regardless of country of origin, issue or publication, which Manufacturer is able to show by clear and convincing evidence
were (i) owned or controlled by Manufacturer on or before the date of this Agreement, or (ii) were conceived by Manufacturer independently
of the carrying out of the Project (i.e., without use of or reference or access to Project Technology or Project Intellectual Property).

 

     

     

    

 

1.5.           “Manufacturer
Background Technology” shall mean all technical information, trade secrets and know-how owned or controlled by
Manufacturer, which Manufacturer is able to show by clear and convincing evidence were (i) owned or controlled by
Manufacturer or its suppliers on or before the date of this Agreement, or (ii) conceived by Manufacturer independently of the
carrying out of the Project (i.e., without use of or reference or access to Project Technology or Project Intellectual
Property).

 

1.6.           
“Product Mold” shall mean a mold, the creation of which is paid for by RareGen, that can be used to manufacture
Cartridges meeting the Specifications designated by RareGen;

 

1.7.           
“Products” shall mean the Cartridges and any related products developed by Manufacturer and RareGen pursuant
to this Agreement and meeting the Specifications supplied by RareGen.

 

1.8.           
“Project” shall mean the overall work of RareGen and Manufacturer, both separately and together, to develop,
produce and manufacture the Products.

 

1.9.           
“Project Intellectual Property” shall mean all patents, patent applications, copyrights or trademarks, regardless
of country of origin, issue or publication, which cover Project Technology or are otherwise related to the Project, except the
Background Technology and Background Intellectual Property.

 

1.10.         
“Project Managers” shall mean the individuals identified as such in Exhibit 3.

 

1.11.         
“Project Technology” shall mean all inventions, ideas and improvements, whether or not patentable, know-how,
trade secrets, copyrights and modifications that are produced, conceived or first actually or constructively reduced to practice
in the course of the work performed pursuant to this Agreement by employees or agents of the Parties or that are in any way related
to the Project, except the Background Technology and Background Intellectual Property. For the avoidance of doubt, the term “Project
Technology” includes any Product Molds developed by Manufacturer as part of the Project and any and all test results and
data generated in connection with the Project.

 

1.12.         
“Purchaser” shall mean, as applicable, RareGen or any third party purchasing Products pursuant to this Agreement
with the prior written consent of RareGen.

 

1.13.         
“RareGen Background Intellectual Property” shall mean all patents, patent applications, copyrights or trademarks
regardless of country of origin, issue or publication, which RareGen is able to show by clear and convincing evidence were (i)
owned or controlled by RareGen on or before the date of this Agreement, or (ii) were conceived by RareGen independently of the
carrying out of the Project (i.e., without use of or reference or access to Project Technology or Project Intellectual Property).

 

1.14.         
“RareGen Background Technology” shall mean all technical information, trade secrets and know-how owned or controlled
by RareGen, which RareGen is able to show by clear and convincing evidence were (i) owned or controlled by RareGen or its suppliers
on or before the date of this Agreement, or (ii) conceived by RareGen independently of the carrying out of the Project (i.e., without
use of or reference or access to Project Technology or Project Intellectual Property).

 

1.15.         
 “Specifications” shall mean those specifications for the Products established by mutual agreement of the Parties
upon completion of the development of the Products. The Specifications for each Product shall be attached to Exhibit 4 upon
the establishment of such Specifications by mutual agreement of the Parties.

 

    2

     

    

 

2.                 
Product Development and Validation.

 

2.1.           
Development Work.

 

(a)              
Manufacturer shall perform those development, validation and testing activities more particularly described on Exhibit
1 (the “Manufacturer Development Work”). Manufacturer shall carry out all of the Manufacturer Development Work
under this Agreement in a timely, diligent, efficient and skillful manner, consistent with high professional and industrial standards.
Manufacturer will furnish competent employees to perform its activities under this Agreement. 

 

(b)              
RareGen shall perform or have a third party perform those development, validation and testing activities more particularly
described on Exhibit 2 (the “RareGen Development Work” and, collectively with the Manufacturer Development Work,
the “Development Work”). RareGen shall carry out all of the RareGen Development Work under this Agreement in a timely,
diligent, efficient and skillful manner, consistent with high professional and industrial standards. RareGen or its Affiliate will
furnish competent employees to perform its activities under this Agreement. 

 

(c)              
The Parties will work together to manage costs and expenses in a reasonably efficient manner. Each Party will require their
employees when on the other's premises to comply with all regulations and policies relative to conduct on the premises. 

 

2.2.           
Project Timeline. Each Party is responsible to the other to report promptly any and all events which may affect the
timing of the Project or such Party’s ability to perform any tasks assigned to it in a timely manner. The target date to
complete the Project and to have commercially available Product is September 1, 2019.

 

2.3.           
Change Control. In the event the Parties desire a change in the scope of the Development Work, a request for changes
must be made in writing and delivered to the other Party’s Project Manager. Both Parties’ Project Managers shall review
the proposed change and either approve it for further investigation or reject it. The investigation shall determine the effect
that the implementation of the change shall have on the Development Work including the time to completion. Upon completion of the
review, any changes in the Development Work or other terms of Exhibit 1 or Exhibit 2 shall be documented in writing
and signed by the Parties’ respective Project Managers. If, despite diligent and good faith negotiations, the Parties fail
to agree on the character or effect of a change to the Development Work, then either (a) the Parties will continue performing the
services hereunder without changes, or (b) the Parties, immediately upon written notice from RareGen, will cease performing the
Development Work.

 

    3

     

    

 

2.4.            Cooperation.
Each Party will use reasonable efforts to provide to the other the full measure of cooperation reasonably required to fulfill
the objectives of this Agreement. Each Party is further responsible to the other to participate in regular reviews of
validation, testing and development, and reviews of any other business issues as they may arise during the term of this
Agreement. The Parties agree to exchange technical and business information pertinent to the Project so that design,
development, testing, and conformance to statutory requirements, manufacturing status, service readiness, timing, and costs
may be monitored and coordinated by RareGen. The Parties will exchange information and assistance which are reasonably
necessary for the other Party to conduct the testing and/or other work under the Project, coordinating all work through their
Project Managers.

 

2.5.           
Project Managers. RareGen and Manufacturer will each assign a Project Manager. The initial Project Managers are identified
in Exhibit 3. Either Party may change its Project Manager by providing written notice to the other, but reasonable effort
will be exercised to maintain continuity to these positions. The Project Managers will coordinate their efforts and have the following
overall responsibilities:

 

(a)              
conduct regular progress meetings and establish ongoing agendas, outlines, and procedures;

 

(b)              
track the overall content and status of the Project, and report on progress to the Parties; and

 

(c)              
carry out any other responsibilities the Parties agree to as the Project progresses.

 

2.6.           
Costs of the Parties.

 

(a)              
Each Party is responsible for providing the necessary systems, personnel, and materials to perform the tasks assigned to
it according to the terms of this Agreement. Except as otherwise expressly set forth herein, each Party shall bear all of the costs
and expenses incurred by it for any deliverables associated with such Party’s Development Work under this Agreement. Except
as otherwise expressly set forth herein, in no event would either Party be entitled to recoup its costs and expenses incurred in
connection with the Project or the Development Work. 

 

(b)              
Notwithstanding the foregoing, RareGen shall be responsible for the following direct costs and expenses: (i) costs and expenses
related to the production of Product Molds, and (ii) third party costs and expenses relating to testing of any Products manufactured
by Manufacturer during the course of the Project as listed in Exhibit 2 in connection with their use with CADD-MS® 3 ambulatory
infusion pumps and/or treprostinil; provided, however, that such tests are approved in advance and in writing by RareGen. 

 

3.                 
Supply of Goods.

 

3.1.           
Distribution of Products. RareGen (or its designated Purchasers) will be the exclusive distributors for all Products
globally.

 

3.2.           
Supply of Cartridges.

 

(a)               Purchasers
may purchase the Products from Manufacturer during the term of this Agreement at the prices agreed to pursuant to Section
3.3 of this Agreement. Manufacturer shall supply such quantities of the Products as Purchasers may order from time to
time during the term of this Agreement on those dates specified in the relevant Orders with minimum order quantity of 100,000
pieces.

 

    4

     

    

 

(b)              
All purchases under this Agreement are subject to issuance of firm purchase orders (“Orders”) by Purchasers.
All Orders, acceptances and other writings or electronic communications between the parties shall be governed by this Agreement.
Any terms in Manufacturer’s acknowledgement of any Order which are in addition to or in conflict with this Agreement or the
Order shall not apply, and a Purchaser’s acceptance of Products shall not be deemed as acceptance of any such terms. In case
of any conflict between this Agreement and any terms set forth in any Order, the terms of this Agreement shall prevail.

 

(c)              
All of the Products shall meet the Specifications and the acceptance criteria agreed by both parties. No substitutions or
changes are to be made without a Purchaser’s written consent. 

 

3.3.           
Pricing. The price to be paid by Purchasers for the Products shall be determined by mutual agreement of such Purchasers
and Manufacturer prior to issuance of each Order, but in each case the price per Cartridge shall be no greater than $[[●]]
per Cartridge (excluding shipping). The prices provided by Manufacturer to any Purchaser shall be as low as the prices at which
Manufacturer is selling (or intending to sell) the same or similar items as the Products to any third party.

 

3.4.           
Payment Terms. Payment for the Product Molds will be 50% payment with PO and 50% before shipment. Any other specific
terms of payment for all Products shall be stated in the relevant Order. Unless otherwise specified in any purchase order or in
a separate written instrument signed by a given Purchaser, Manufacturer shall indicate the appropriate purchase order number on
the invoice and shall deliver it to the address specified by the applicable Purchaser from time to time.

 

4.                 
Intellectual Property Rights.

 

4.1.           
Project Technology and Project Intellectual Property.

 

(a)              
Manufacturer will promptly disclose in confidence to RareGen all Project Technology and Project Intellectual Property that
Manufacturer (or its employees or other persons working on its behalf) makes, conceives or first reduces to practice or creates
during the term of this Agreement, whether or not such Project Technology or Project Intellectual Property is patentable, copyrightable
or able to be protected as trade secrets, trademarks or service marks, or otherwise able to be registered or protected by law.

 

(b)               Manufacturer
agrees that all Project Technology and Project Intellectual Property will be the sole and exclusive property of RareGen and
are hereby irrevocably assigned by Manufacturer to RareGen related to the Products. Upon RareGen’s request and provided
that RareGen pays all related expenses, Manufacturer agrees to provide reasonable assistance to RareGen for the purposes of
obtaining for RareGen and enforcing patents, copyrights, mask work rights, trade secret rights and other legal protections in
any and all countries for the Project Technology and Project Intellectual Property that are owned by RareGen pursuant to this
Section 4.1 or otherwise. Manufacturer will execute any documents that RareGen may reasonably request for use in
obtaining or enforcing such patents, copyrights, mask work rights, trade secrets and other legal protections.
Manufacturer’s obligations under this section will continue beyond the term of this Agreement.

 

    5

     

    

 

4.2.           
Background Technology and Background Intellectual Property. If any of Manufacturer’s Background Technology
or Background Intellectual Property is used or incorporated in the Project or any Project deliverables, then Manufacturer grants
to RareGen a perpetual, fully paid-up, non-exclusive, irrevocable, worldwide, royalty-free, assignable, sublicenseable license
to use all Background Technology and Background Intellectual Property that is required in order to use the Project Technology or
Project Intellectual Property or required to practice the Project Technology or Project Intellectual Property for the purposes
of making, having made, using, having used, selling, offering to sell, licensing and importing Products, components thereof and/or
any goods or products derived therefrom or based thereon.

 

4.3.           
Survival of Rights. Termination of this Agreement shall not affect the rights of RareGen or Manufacturer with respect
to the Project Technology, Project Intellectual Property, Background Technology and Background Intellectual Property as set forth
in this Section 4, which rights shall survive the termination of this Agreement indefinitely.

 

5.                 
Confidentiality.

 

5.1.           
General. Each Party (the “Receiving Party”) agrees to hold confidential for the sole benefit of the other
Party (the “Disclosing Party”) all such secret, confidential or proprietary information, knowledge, data or trade secrets
(“Confidential Information”) relating to the Disclosing Party or its affiliates. By way of example, for purposes of
this Agreement, Confidential Information shall be deemed to include, but not be limited to, any of the following relating to the
Disclosing Party: existing and contemplated products, formulae, inventions, designs, methods, know-how, techniques, systems, processes,
customer lists, projects, pricing, costs, revenues and engineering, manufacturing, testing, operational and marketing plans, advertising
or marketing channels, methods or partners, reports, analyses, proposals and procedures and current or anticipated research and
development. In addition, (i) this Agreement and the terms hereof and the relationship of the Parties created hereunder shall be
deemed to be Confidential Information of both Parties for purposes hereof, and (ii) the Project Intellectual Property, Project
Technology and all other information relating to the Project and the Products shall be deemed to be Confidential Information of
RareGen for purposes hereof. Receiving Party agrees that, except as necessary to fulfill its obligations hereunder, Receiving Party
will not at any time, either prior to or during the Term or after its termination for any reason whatsoever, disclose to anyone
any Confidential Information of Disclosing Party, or use such Confidential Information for any purpose other than as necessary
and required to perform the Development Work hereunder.

 

5.2.            Exceptions.
The foregoing notwithstanding, the following shall not be Confidential Information for purposes of this Agreement: (a)
information that had otherwise become known to Receiving Party other than through carrying out of the Project, performance of
the Development Work, or the disclosure by Disclosing Party, its affiliates or its representatives or any other source known
by Receiving Party to be under an obligation of confidentiality to Disclosing Party or its affiliates with respect to such
information; (b) information that is or becomes publicly known without breach of this Agreement by Receiving Party; and (c)
information that is discovered or conceived by Receiving Party independently of the carrying out of the Project or
performance of the Development Work and without use of or reference or access to Disclosing Party’s Confidential
Information.

 

    6

     

    

 

5.3.           
Compelled Disclosure. In the event that, at any time during the Term or at any time thereafter, Receiving Party receives
a request to disclose all or any part of Confidential Information under the terms of a subpoena or order issued by a court or by
a governmental body, Receiving Party agrees (i) to notify Disclosing Party immediately of the existence, terms and circumstances
surrounding such request, (ii) to consult with Disclosing Party on the advisability of taking legally available steps to resist
or narrow such request or delay response to such request so as to allow Disclosing Party adequate time to seek protection of such
Confidential Information, (iii) if disclosure of such trade secrets and other proprietary and confidential information is required
to prevent Receiving Party from being held in contempt or subject to other penalty, to furnish only such portion of the trade secrets
and other proprietary and confidential information as, in the opinion of counsel satisfactory to Disclosing Party, Receiving Party
is legally compelled to disclose and (iv) to exercise Receiving Party’s reasonable efforts and to cooperate with Disclosing
Party’s efforts to obtain a protective order or other reliable assurance that confidential treatment will be accorded to
the disclosed trade secrets and other proprietary and confidential information.

 

5.4.           
Survival of Obligations. Termination of this Agreement shall not affect the rights and obligations of the Parties
with respect to Confidential Information disclosed or received under this Agreement prior to termination. Receiving Party will
continue to protect all Confidential Information as required herein.

 

5.5.           
Return of Materials Containing Confidential Information. At the option of Disclosing Party, upon termination of this
Agreement, Receiving Party shall return or, if requested by Disclosing Party, destroy all tangible Confidential Information of
Disclosing Party.

 

5.6.           
Conflicts. The Parties agree that this Section 5 shall not affect the rights and licenses granted under Section
4 hereof. Thus, in the event of any conflict between this Section 5 and Section 4 or in the event the restrictions
set forth in this Section 5 would make the use of the rights and licenses described in Section 4 impractical, Section
4 shall control and this Section 5 shall be deemed to have been automatically amended to the minimum extent necessary
to eliminate such conflict or impracticality.

 

6.                 
Information. With respect to all development and other work performed or products supplied by Manufacturer, Manufacturer
will provide to RareGen on a timely basis full and complete copies of any and all information reasonably related to the Products
and the development thereof. Such information shall include all design calculations, analyses and test results, whether analytical
or physical, plans, photographs, patterns, models, test specifications, tooling designs and technical information which involve
the Products. Notwithstanding anything to the contrary set forth herein, RareGen shall have the right to use any and all data acquired
from Manufacturer as part of the services rendered hereunder for marketing, promotional and other purposes.

 

    7

     

    

 

7.                  Restrictions
on Use of RareGen Confidential Information and Intellectual Property. Manufacturer acknowledges and agrees that the
Product Molds developed for RareGen and the results of tests performed on Products developed hereunder shall constitute
RareGen’s Confidential Information and Project Intellectual Property. Accordingly, Manufacturer agrees that it shall
not use such Product Molds or test results in connection with or for purposes of manufacturing any products without
RareGen’s prior written consent.

 

8.                 
Injunctive Relief. Manufacturer understands and agrees that RareGen will suffer irreparable harm in the event
that Manufacturer breaches any of Manufacturer’s obligations under Sections 4, 5 and 7 hereof and that monetary damages will
be inadequate to compensate RareGen for such breach. Accordingly, Manufacturer agrees that, in the event of a breach or threatened
breach by Manufacturer of any of the provisions of Sections 4, 5 or 7 hereof, RareGen, in addition to and not in limitation of
any other rights, remedies or damages available to RareGen at law or in equity, shall be entitled to a temporary restraining order,
preliminary injunction and/or permanent injunction in order to prevent or to restrain any such breach by Manufacturer, or by any
or all of Manufacturer’s partners, co-venturers, employers, employees, servants, agents, representatives and any and all
persons directly or indirectly acting for, on behalf of or with Manufacturer.

 

9.                 
Manufacturer’s Representations, Warranties and Covenants. Manufacturer represents, warrants and covenants
to RareGen as follows:

 

9.1.           
Manufacturer’s performance of all the terms of this Agreement and any Manufacturer Development Work to be performed
hereunder do not and will not breach any fiduciary or other duty or any covenant, agreement or understanding (including, without
limitation, any agreement relating to any proprietary information, knowledge or data acquired by Manufacturer in confidence, trust
or otherwise prior to the date hereof) to which Manufacturer is or may in the future become a party or by the terms of which Manufacturer
may be bound.

 

9.2.           
Manufacturer will not disclose to RareGen, or induce RareGen to use, any such proprietary information, knowledge or data
belonging to any third party.

 

9.3.           
Manufacturer will not to enter into any agreement or understanding, either written or oral, in conflict with the provisions
of this Agreement.

 

9.4.           
Manufacturer can not represent and warrant that the Manufacturer Development Work and the deliverables provided with respect
thereto do not constitute an infringement or violation of any patent, copyright, trade secret or other proprietary rights of any
third party. Manufacturer only responsible to produce the products according to the specification that provided by RareGen.

 

9.5.            Manufacturer
warrants that the Manufacturer Development Work provided under this Agreement shall be performed in a good and workmanlike manner
in accordance with generally established professional standards and practices for such services and in accordance with the best
practices in Manufacturer’s industry, and that such Manufacturer Development Work will comply with all laws, regulations,
codes, and ordinances.

 

    8

     

    

 

10.             
RareGen’s Representations, Warranties and Covenants. RareGen represents, warrants and covenants to Manufacturer
as follows:

 

10.1.        RareGen’s
performance of all the terms of this Agreement and any RareGen Development Work to be performed hereunder do not and will not
breach any fiduciary or other duty or any covenant, agreement or understanding (including, without limitation, any agreement
relating to any proprietary information, knowledge or data acquired by RareGen in confidence, trust or otherwise prior to the
date hereof) to which RareGen is or may in the future become a party or by the terms of which RareGen may be bound.

 

10.2.       
RareGen will not disclose to Manufacturer, or induce Manufacturer to use, any such proprietary information, knowledge or
data belonging to any third party.

 

10.3.       
RareGen will not to enter into any agreement or understanding, either written or oral, in conflict with the provisions of
this Agreement.

 

10.4.       
RareGen represents and warrants that the RareGen Development Work and the deliverables provided with respect thereto do
not constitute an infringement or violation of any patent, copyright, trade secret or other proprietary rights of any third party.

 

10.5.       
RareGen warrants that the RareGen Development Work provided under this Agreement shall be performed in a good and workmanlike
manner in accordance with generally established professional standards and practices for such services and in accordance with the
best practices in RareGen’s industry, and that such RareGen Development Work will comply with all laws, regulations, codes,
and ordinances.

 

11.             
Indemnification; Limitation of Liability; Insurance.

 

11.1.       
Manufacturer shall indemnify and hold RareGen and its Affiliates harmless from any losses, damages, liabilities, costs,
fees or expenses (including reasonable attorneys' fees) incurred by RareGen in connection with any (i) misrepresentation or breach
by Manufacturer of any warranty, covenant or agreement made or contained in this Agreement, and (ii) claim or action instituted
or threatened against RareGen based upon any Manufacturer Development Work involving any claim for infringement of any patent,
trademark, copyright or other proprietary or intellectual property right.

 

11.2.       
RareGen shall indemnify and hold Manufacturer and its affiliates harmless from any losses, damages, liabilities, costs,
fees or expenses (including reasonable attorneys' fees) incurred by Manufacturer in connection with any (i) misrepresentation or
breach by RareGen of any warranty, covenant or agreement made or contained in this Agreement, and (ii) claim or action instituted
or threatened against Manufacturer based upon any RareGen Development Work involving any claim for infringement of any patent,
trademark, copyright or other proprietary or intellectual property right.

 

11.3.       
EXCEPT IN CONNECTON WITH A BREACH OF SECTIONS 4, 5 OR 7 OR WILLFUL MISCONDUCT, IN NO EVENT WILL EITHER PARTY BE LIABLE
TO THE OTHER PARTY FOR ANY SPECIAL, EXEMPLARY, INCIDENTAL, INDIRECT, PUNITIVE, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED
TO, LOST PROFITS, REVENUE, AND BUSINESS), WHETHER BASED ON BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE), STATUTE, EQUITY, PRODUCT
LIABILITY, FUNDAMENTAL BREACH, OR OTHERWISE ARISING FROM OR RELATED TO THIS AGREEMENT, REGARDLESS OF WHETHER OR NOT THE OTHER
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF ANY SUCH DAMAGES.

 

    9

     

    

  

11.4.     
Each Party undertakes to maintain a comprehensive liability insurance policy with a reputable insurer including coverage
for third party liability and product liability on commercially reasonable terms. Such insurance shall be for an insured sum of
not less than $2,000,000. Upon execution of this Agreement, each Party shall furnish the other Party with certificates of insurance
and with signed endorsements affecting coverage required by this Section 11. Each Party shall notify the other Party at least thirty
(30) calendar days prior to the cancellation of, or any modification in, such insurance policy that would affect such other Party’s
status or benefits hereunder. Each Party shall furnish to the other Party evidence, in form and substance satisfactory to such
other Party, of the maintenance and renewal of the required insurance including, but not limited to, copies of policies with applicable
riders and endorsements, and certificates of insurance.

 

12.             
Additional Terms.

 

12.1.      
Force Majeure. Any delay or failure of either Party to perform its obligations under this Agreement shall be excused
if such Party is unable to produce, sell or deliver, or to accept delivery, buy or use, the goods or services covered by this Agreement,
as the result of an event or occurrence beyond the reasonable control of the Party and without its fault or negligence, including,
but not limited to the following types of events or occurrences (but only if such events or occurrences meet the foregoing limitations
regarding control, fault and negligence): acts of God, actions by any governmental authority (whether valid or invalid), fires,
floods, windstorms, explosions, riots, natural disasters, wars, sabotage, labor problems (including lockouts, strikes and slowdowns),
inability to obtain power, material, labor equipment or transportation, or court injunction or order; provided that written notice
of such delay (including the anticipated duration of the delay) shall be given by the affected Party to the other Party as soon
as possible after the event or occurrence (but in no event more than ten (10) days thereafter) and provided that the Party claiming
force majeure has exerted all reasonable efforts to avoid or remedy such force majeure.

 

12.2.      
Term and Termination.

 

(a)              
This Agreement will remain in effect from the date hereof through the eighth (8th) anniversary of the date hereof;
provided, however, that RareGen may terminate this Agreement at any time prior thereto upon 30 days’ advance written notice
to Manufacturer. Outstanding payments will remain due and payable until paid and open purchase orders will be filled based on mutual
agreement.

 

(b)              
In the event of any expiration or termination of this Agreement, the rights and obligations set forth in Sections 4, 5,
6, 7, 8, 9, 10, 11 and 12 of this Agreement shall survive and remain in full force and effect indefinitely or in accordance with
the terms thereof.

 

12.3.      
Notices.

 

(a)               All
notices, consents, waivers and other communications hereunder must be in writing and either (i) delivered personally, (ii)
sent by electronic mail transmission (with written confirmation, which may be by electronic mail, of a successful
transmission), (iii) mailed by prepaid first class registered or certified mail, return receipt requested, or (iv) delivered
by a nationally-recognized prepaid overnight courier service (receipt requested), in each case to the appropriate
addresses or e-mail addresses set forth below (or to such other addresses or e-mail addresses as a Party may designate by
notice to the other Parties):

 

    10

     

    

 

	 	If to RareGen:  	RareGen, LLC	 
	 	 	c/o PBM Capital Group, LLC	 
	 	 	200 Garrett Street, Suite S	 
	 	 	Charlottesville, VA 22902	 
	 	 	E-mail: legal@pbmcap.com	 
	 	 	 
	 	If to Manufacturer:	Carelife USA Inc.	 
	 	 	c/o ________________________	 
	 	 	4319 Abbotts Bridge Road, Suite 3	 
	 	 	Duluth, GA 30097	 
	 	 	E-mail: g.hammond@carelifeusa.com	 
	 	 	 

(b)              
All such notices, consents, waivers and other communications will (i) if delivered personally in the manner and to the address
provided in this section, be deemed given upon delivery, (ii) if delivered by electronic mail in the manner and to the e-mail address
provided in this section, be deemed given on the earlier of receipt or the first business day after transmission, (iii) if delivered
by mail in the manner, and to the address provided in this section, be deemed given on the earlier of the fourth business day following
mailing or upon receipt, and (iv) if delivered by overnight courier in the manner and to the address provided in this section,
be deemed given on the earlier of receipt or the first business day following the date sent by such overnight courier. 

 

12.4.      
Independent Contractors; No Partnership.

 

(a)              
Each Party shall be an independent contractor only for the purpose and to the extent set forth in this Agreement, and none
of either Party’s employees shall be deemed to be employees of the other Party with respect to any Development Work performed
hereunder or otherwise. As an independent contractor hereunder, each Party shall have complete charge of any persons engaged by
such Party in the performance of its Development Work hereunder. 

 

(b)              
Neither Party has any authority, actual or apparent, to act on behalf of the other Party. In particular, neither Party has
authority to bind the other Party by any promise or representation. 

 

(c)              
Nothing in this Agreement shall be construed or implied to create a relationship of partners, agency, or joint venture between
RareGen and Manufacturer.

 

12.5.      
Compliance with Laws. Each Party will comply with all laws, regulations and standards applicable to its work hereunder.

 

12.6.       Reliance
upon Information. Neither Party makes any warranty with respect to any information, documents, materials or assistance
provided the other in the course of negotiating this Agreement. However, to the extent that one Party relies on testing
performed by the other Party or such other Party’s subcontractor or service provider for purposes of validation or
certification, the Party performing or commissioning such testing warrants that each test has been performed in accordance
with the written test request, and that the test results are true and accurate.

 

    11

     

    

 

12.7.     
Trademarks. Each Party agrees that it shall not use any trademarks of the other Party except with the prior written
consent of the other Party and in compliance with such policies and procedures relating to the use of the trademarks such other
Party may adopt from time to time, in its sole discretion.

 

12.8.     
Waiver. No term of this Agreement shall be considered waived, and no breach shall be excused, by either party unless
the parties mutually agree in writing. No consent, waiver, or excuse by either party, whether express or implied, shall constitute
a subsequent consent, waiver, or excuse.

 

12.9.     
Assignability. Except RareGen’s right to assign to Purchasers the right to purchase Products hereunder, neither
Party may assign or delegate its rights or obligations under this Agreement without the other Party’s prior written consent.
Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors
and assigns.

 

12.10.   
Severability. If any term(s) of this Agreement is invalid or unenforceable under any statute, regulation, ordinance,
executive order or other rule of law, such term(s) shall be deemed reformed or deleted, as the case may be, but only to the extent
necessary to comply with such statute, regulation, ordinance, order or rule, and the remaining provisions of this Agreement shall
remain in full force and effect.

 

12.11.   
Binding upon Affiliates. The Parties recognize that their respective Affiliates may participate in aspects of this
Agreement. In such case, the Parties will cause their respective Affiliates to comply with the procedures and terms and conditions
set forth herein.

 

12.12.   
Entire Understanding, Amendments. This Agreement, along with the Exhibits hereto, embodies the entire understanding
between the parties relating to the subject matter hereof and there are no prior representations or warranties between the parties
relating thereto. No amendments, modifications, renewal, extension or waiver of this Agreement or any of its provisions shall be
binding unless the parties mutually agree in a subsequent writing, duly executed by an authorized officer of each party, which
specifies that the subsequent writing is a supplement or amendment hereof. To the extent that any of the terms of this Agreement
are inconsistent with the terms of any Exhibit hereto, the terms of this Agreement shall control.

 

12.13.   
Counterparts; Electronic Transmission. This Agreement may be executed in one or more counterpart copies, each of
which will be deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to constitute
one and the same agreement. The exchange of copies of this Agreement and of signature pages by electronic transmission shall constitute
effective execution and delivery of this Agreement as to the Parties and may be used in lieu of the original Agreement for all
purposes. Signatures of the Parties transmitted by electronic transmission shall be deemed to be their original signatures for
all purposes.

 

    12

     

    

 

12.14.    Applicable
Law; Dispute Resolution. This Agreement shall be governed by and interpreted, construed, and enforced in accordance with
the laws of the State of Delaware, excluding its rules on conflicts of law. The United Nations Convention on Contracts for
International Sales of Goods does not apply to this Agreement. The Parties will attempt to resolve any dispute, controversy
or claim relating to this Agreement (a “Dispute”) through good faith negotiations within a reasonable time period
(such time period not to exceed forty-five (45) days). If the Dispute is not resolved through negotiation, either Party may
submit the Dispute to the courts located in the State of Delaware. With regards to any action for breach of Sections 4, 5 or
7 hereof, nothing in this Section shall preclude either Party from seeking interim equitable relief in the form of a
temporary restraining order or preliminary injunction.

 

Now, therefore, the
Parties hereby agree and have caused this Agreement to be signed by their duly authorized representatives in duplicate as of the
date first set forth above.

 

	
        RAREGEN, LLC

        
	 	Carelife USA Inc. 
	 	 	 
	By:	/s/ Damian deGoa	 	By:	/s/ Grace Hammond
	Name: 	Damian deGoa	 	Name: 	Grace Hammond
	Title:	Chief Executive Officer	 	Title:	VP

 

    13

     

    

 

Exhibit 1

 

MANUFACTURER DEVELOPMENT WORK

 

§    
Development, design and manufacturing of Product Molds based on specifications provided by RareGen;

 

§    
Development, design and manufacturing of Products based on specifications provided by RareGen;

 

§    
Other cooperation with and assistance to RareGen as reasonably necessary for the Project;

 

§    
Perform all testing required for regulatory clearance with U.S. FDA, including but not limited to ISO 10993 sterility, shipping
testing ASTM and environment conditions exposure, and full FAI testing of all critical dimensions. Manufacturer may waive testing
requirements if they can substantiate previous completed testing is applicable to the Products.

 

§    
Manufacture Products according to cGMP and in compliance with ISO13485 and U.S. FDA regulations; and

 

§    
This product will be filed under our existing 510K for syringes, K132553. We will not be able to apply another 510K to indicate
for use with CADD-MS 3 ambulatory infusion pump. We also will not be able to print on the label indicating this syringe is for
CADD-MS 3 ambulatory infusion pump.

 

Manufacturer will not be responsible for
the product patent issues related to this product, manufacturer will only produce the products according to the purchaser’s
requirements.

 

    

     

    

 

 

Exhibit 2

 

RAREGEN DEVELOPMENT WORK

 

§    
Securing of sales and distribution channels;

§    
Decisions on concept and Specifications;

§    
Performance testing of the Product with the CADD MS-3 Pump

§    
Fit testing of the Product with the CADD MS-3 Pump

§    
Stability testing of the Product with the treprostinil drug

§    
Other cooperation with and assistance to Manufacturer as reasonably necessary for the Project.

 

    

     

    

 

Exhibit 3

 

PROJECT MANAGERS

 

	1. 	Project Managers:	 
	 	 
	  	RareGen Project Manager: 	Gene Scavola	 
	 	 	 	 
	 	 	Damian deGoa	 	 
	 	 	 	 
		Manufacturer Project Manager:	 
	 	 	Grace Hammond	 	 
	 	 	 	 
	 	 	 	 

 

    

     

    

 

 

Exhibit 4

 

SPECIFICATIONS

 

DRAFT Specifications included. Will be mutually updated by parties
during development.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]